Daiichi Sankyo Company, Limited (Daiichi Sankyo) announced that the
oncolytic virus therapy for cancer (G47?) jointly developed with Dr.
Tomoki Todo, a professor at the University of Tokyo’s Institute of
Medical Science, has been designated under the SAKIGAKE Designation
System for medical equipment and in vitro diagnostic pharmaceuticals and
regenerative medicine products, which was launched this year.
Professor Todo initiated the GCP based second-phase G47? clinical trial targeting glioblastoma in 2015. G47? has performed well in the study, and non-clinical researches and clinical researches for other carcinomas have already begun. Based on data obtained thus far, it has also been suggested that there is a possibility of expanding indications to other types of cancer. In the future, Daiichi Sankyo intends to collaborate with Professor Todo on the further development of this cancer treatment method.
Daiichi Sankyo remains committed to meeting the needs of more patients and medical professionals through drug development and contributing to medical care by providing new treatment options.
Professor Todo initiated the GCP based second-phase G47? clinical trial targeting glioblastoma in 2015. G47? has performed well in the study, and non-clinical researches and clinical researches for other carcinomas have already begun. Based on data obtained thus far, it has also been suggested that there is a possibility of expanding indications to other types of cancer. In the future, Daiichi Sankyo intends to collaborate with Professor Todo on the further development of this cancer treatment method.
Daiichi Sankyo remains committed to meeting the needs of more patients and medical professionals through drug development and contributing to medical care by providing new treatment options.
No comments:
Post a Comment